Clinical and pathological parameters predicting pathologic complete response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer

ERCC1, as Prognostic and Predictive Marker in Metastatic Colorectal Cancer Patients Treated with Oxaliplatin based Chemotherapy

Lymphocytic Count and Ratio as Predictive Factors for Pathological Response after Neoadjuvant Therapy in Patients with Rectal Cancer

Association between COX-2 Gene Polymorphism and Susceptibility to Colon and Rectal Cancer

Impact of neoadjuvant chemoradiation on pathologic response and survival of patients with rectal cancer

Study of Association of MTHFR C677T Gene Polymorphism and Folate Level in Colorectal Cancer Patients

Potential Association of Poly(ADP-ribose) Polymerase-1 (PARP-1) with CD133 and G2/M as Independent Predictors in Colorectal Cancer Development.

FOXP3 Expression as a Biomarker in Metastatic Colorectal Cancer Treated with Irinotecan-based Therapy

Downstaging of Rectal Cancer Following Neoadjuvant Chemoradiotherapy; How Far Could Functional MRI Support Organ Preservation Approach

Complex Interplay of CYP1A1 Genetic Polymorphism on Colorectal Cancer Susceptibility